CAJ | 학술논문

白血病患者骨髓CYR61、CTGF、VEGF-C、VEGFR-2mRNA的表达及其临床意义
백혈병환자골수CYR61、CTGF、VEGF-C、VEGFR-2mRNA적표체급기림상의의
Expression of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA in Bone Marrow of Leukemia Patients and Its Clinical Significance

万方数据

中国实验血液学杂志中國實驗血液學雜誌 중국실험혈액학잡지
JOURNAL OF EXPERIMENTAL HEMATOLOGY
2011年 6期 1368-1373 ,共6页

徐宁%贺其图%卢燕%韩轩茂%马宏杰%张冬霞%刘学文%袁晓俊%贾国荣%李静%李喆%李志芹%韩海燕

서저%하기도%로연%한헌무%마굉걸%장동하%류학문%원효준%가국영%리정%리철%리지근%한해연

白血病%富含半胱氨酸蛋白61%结缔组织生长因子%血管内皮生长因子-C%血管内皮生长因子受体-2 白血病%富含半胱氨痠蛋白61%結締組織生長因子%血管內皮生長因子-C%血管內皮生長因子受體-2
백혈병%부함반광안산단백61%결체조직생장인자%혈관내피생장인자-C%혈관내피생장인자수체-2

本研究检测白血病患者骨髓中CYR61、CTGF、VEGF-C、VEGFR-2 mRNA的表达水平,探讨白血病发生、发展、浸润、转移中CYR61、CTGF、VEGF-C、VEGFR-2蛋白的相互作用及其临床意义,寻找新的肿瘤标记物,为白血病的诊治提供新的思路.白血病74例,男38例,女36例,年龄6 - 77岁,中位年龄45岁.对照组12例,男7例,女5例.年龄16 -78岁,中位年龄46岁.采用半定量逆转录聚合酶链反应(RT-PCR)方法测定CYR61、CTGF、VEGF-C、VEGFR-2 mRNA的水平.结果表明,各组初发急性和慢性白血病患者骨髓中CYR61、CTGF、VEGF-C、VEGFR-2 mRNA的表达与对照组相比均显著升高(p＜0.05).急性白血病缓解后CYR61和CTGF mRNA的表达高于对照组(p =0.039,0.025).CTGF mRNA的表达在B-ALL组表达最高,高于AML、CML、CLL、T-ALL组(p=0.002,0.034,0.002,0.010).AML组CYR61与CTGF、CYR61与VEGF-C、CTGF与VEGFR-2 mRNA的表达均呈正相关(r =0.452,0.466,0.464;p =0.045,0.038,0.039),CML组CYR61与VEGF-C mRNA的表达呈正相关(r=0.882,p=0.000).急性白血病伴有髓外浸润者VEGF-C和VEGFR-2 mRNA的表达高于不伴有髓外浸润者(p=0.028,0.047).AML组VEGF-C mRNA的表达与原始细胞数呈正相关(r =0.418,p=0.034).结论:CYR61、CTGF及VEGF-C、VEGFR-2在白血病发病中相互作用,促进白血病发展、转移及浸润;且这些因子在不同类型白血病及髓外浸润中的作用存在差异.它们可能成为检测白血病的肿瘤标记物;阻断上述因子有可能阻断肿瘤的生长和转移.
본연구검측백혈병환자골수중CYR61、CTGF、VEGF-C、VEGFR-2 mRNA적표체수평,탐토백혈병발생、발전、침윤、전이중CYR61、CTGF、VEGF-C、VEGFR-2단백적상호작용급기림상의의,심조신적종류표기물,위백혈병적진치제공신적사로.백혈병74례,남38례,녀36례,년령6 - 77세,중위년령45세.대조조12례,남7례,녀5례.년령16 -78세,중위년령46세.채용반정량역전록취합매련반응(RT-PCR)방법측정CYR61、CTGF、VEGF-C、VEGFR-2 mRNA적수평.결과표명,각조초발급성화만성백혈병환자골수중CYR61、CTGF、VEGF-C、VEGFR-2 mRNA적표체여대조조상비균현저승고(p＜0.05).급성백혈병완해후CYR61화CTGF mRNA적표체고우대조조(p =0.039,0.025).CTGF mRNA적표체재B-ALL조표체최고,고우AML、CML、CLL、T-ALL조(p=0.002,0.034,0.002,0.010).AML조CYR61여CTGF、CYR61여VEGF-C、CTGF여VEGFR-2 mRNA적표체균정정상관(r =0.452,0.466,0.464;p =0.045,0.038,0.039),CML조CYR61여VEGF-C mRNA적표체정정상관(r=0.882,p=0.000).급성백혈병반유수외침윤자VEGF-C화VEGFR-2 mRNA적표체고우불반유수외침윤자(p=0.028,0.047).AML조VEGF-C mRNA적표체여원시세포수정정상관(r =0.418,p=0.034).결론:CYR61、CTGF급VEGF-C、VEGFR-2재백혈병발병중상호작용,촉진백혈병발전、전이급침윤;차저사인자재불동류형백혈병급수외침윤중적작용존재차이.타문가능성위검측백혈병적종류표기물;조단상술인자유가능조단종류적생장화전이.